Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Unknown field was ignored: [Corporate Author]
Page 1
Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers.
Novelli S, Bento L, Garcia I, Prieto L, López L, Gutierrez G, Hernani R, Pérez A, Esquirol A, Solano C, Bastos M, Dorado N, Rodríguez N, Rodríguez G, Piñana JL, Montoro J, Herrera P, Luna A, Parody R, Martín C, García E, López O, Heras I, Zanabili J, Moraleda JM, Yañez L, Gutierrez A, Zudaire T, Córdoba R, Varela R, Ferra C, Martínez J, Martínez C, Gonzalez-Barca E, Martino R, Caballero D; GELTAMO and GETH. Novelli S, et al. Transplant Cell Ther. 2021 Jun;27(6):493.e1-493.e8. doi: 10.1016/j.jtct.2021.03.014. Epub 2021 Mar 15. Transplant Cell Ther. 2021. PMID: 33857447 Free article.
We aim to report the results of alloSCT for advanced mature T and NK/T neoplasias performed in centers from our national GELTAMO/GETH (Grupo Espanol de Linfoma y Trasplante de Medula Osea/Grupo …
We aim to report the results of alloSCT for advanced mature T and NK/T neoplasias performed in centers from our national GELTAMO/G …
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
Martínez C, de Haro ME, Romero S, Gutiérrez A, Domingo-Domènech E, González-Rodríguez AP, Zeberio I, Martínez-Badas MP, Rodríguez-Izquierdo A, Carpio C, Bastos-Oreiro M, Hernández-Rivas JÁ, Vallansot R, Kelleher N, Díaz-Gálvez FJ, Torrado T, Pereira A, García-Sanz R; Grupo Español de Linfoma y Trasplante de Médula Ósea (GELTAMO) y Grupo Español de Trasplante (GETH). Martínez C, et al. Ann Hematol. 2023 Feb;102(2):429-437. doi: 10.1007/s00277-022-05011-6. Epub 2022 Nov 12. Ann Hematol. 2023. PMID: 36370191 Free article.